Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Zevra Therapeutics has a “Moderate Buy” consensus rating from 10 analysts, with nine buys and one hold. The average 12-month price target is $27.14 versus a recent share price of $11.57.
• The company reported quarterly EPS of $0.25, beating estimates of $0.11, while revenue of $39.66 million exceeded expectations of $33.88 million. Analysts expect full-year EPS of $0.60.
• Institutional ownership stands at 35.03%, with several funds increasing their positions, while director Corey Michael Watton sold 12,300 shares at an average price of $11.25.

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $27.1429.

A number of equities research analysts have recently commented on the company. Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $29.00 to $20.00 and set a "buy" rating on the stock in a research report on Monday, July 27th. Maxim Group boosted their price objective on Zevra Therapeutics from $25.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday, June 10th. Citizens Jmp increased their target price on Zevra Therapeutics from $25.00 to $28.00 and gave the stock a "market outperform" rating in a research note on Thursday, August 6th. Weiss Ratings downgraded shares of Zevra Therapeutics from a "buy (b-)" rating to a "hold (c)" rating in a report on Friday, May 22nd. Finally, Cantor Fitzgerald raised their target price on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the stock an "overweight" rating in a report on Monday, June 8th.

Zevra Therapeutics Stock Up 0.3%

Shares of ZVRA stock opened at $11.57 on Wednesday. Zevra Therapeutics has a 12-month low of $7.16 and a 12-month high of $15.03. The firm has a fifty day moving average of $12.30 and a 200-day moving average of $10.71. The firm has a market capitalization of $687.03 million, a price-to-earnings ratio of 12.58 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.11 by $0.14. The business had revenue of $39.66 million for the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. Research analysts expect that Zevra Therapeutics will post 0.6 earnings per share for the current year.

Insider Activity

In other news, Director Corey Michael Watton sold 12,300 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the sale, the director owned 1,800 shares of the company's stock, valued at $20,250. This represents a 87.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC bought a new stake in shares of Zevra Therapeutics in the first quarter valued at about $11,184,000. Dimensional Fund Advisors LP grew its holdings in shares of Zevra Therapeutics by 259.2% during the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company's stock worth $5,168,000 after buying an additional 400,336 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Zevra Therapeutics by 116.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company's stock worth $5,502,000 after buying an additional 206,543 shares in the last quarter. UBS Group AG raised its position in Zevra Therapeutics by 30.9% in the 4th quarter. UBS Group AG now owns 285,488 shares of the company's stock valued at $2,558,000 after buying an additional 67,392 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its position in Zevra Therapeutics by 16.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company's stock valued at $2,207,000 after buying an additional 33,951 shares during the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source